Double-blind randomized phase II results comparing concurrent high-dose cisplatin chemorradiation (CRT) plus debio 1143 or placebo in high-risk patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN): A GORTEC study

被引：0
|
作者：
Bourhis, J. [1 ]
Sun, X. [2 ]
Pointreau, Y. [3 ]
Sire, C. [4 ]
Le Tourneau, C. [5 ]
Coutte, A. [6 ]
Kaminsky-Forrett, M-C. [7 ]
Alfonsi, M. [8 ]
Boisselier, P. [9 ]
Martin, L. [10 ]
Delord, J-P. [11 ]
Clatot, F. [12 ]
Miroir, J. [13 ]
Rolland, F. [14 ]
Crompton, P. [15 ]
Brienza, S. [15 ]
Szyldergemajn, S. A. [15 ]
Even, C. [16 ]
Tao, Y. [17 ]
机构：
[1] CHU Vaudois, Radiat Oncol, Lausanne, Switzerland
[2] HNFC, Radiat Oncol, Belfort, France
[3] Ctr Jean Bernard, Radiat Oncol, Le Mans, France
[4] Hop Scorff, Ctr Hosp Bretagne Sud, Radiat Oncol, Lorient, France
[5] Inst Curie, Med Oncol, Paris, France
[6] CHU Amiens Picardie Site Nord, Oncol Radiotherapy, Amiens, France
[7] Inst Cancerol Lorraine Alexis Vautrin, Radiat Oncol, Vandoeuvre Les Nancy, France
[8] Inst Ste Catherine, Radiat Oncol, Avignon, France
[9] ICM Reg Canc Inst Montpellier, Radiat Oncol, Montpellier, France
[10] Ctr Radiotherapie Gillaume Le Conquerant, Radiat Oncol, Le Havre, France
[11] Inst Univ Canc Toulouse Oncopole, Med Oncol, Toulouse, France
[12] Ctr Henri Becquerel, Med Oncol, Rouen, France
[13] Ctr Jean Perrin, Radiat Oncol, Clermont Ferrand, France
[14] ICO Inst Cancerol Ouest Rene Gauducheau, Radiat Oncol, St Herblain, France
[15] Debiopharm Int SA, CR&D, Lausanne, Switzerland
[16] Inst Gustave Roussy, Med Oncol, Villejuif, France
[17] Inst Gustave Roussy, Radiat Oncol, Villejuif, France
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA65
引用
收藏
页码：902 / 902
页数：1
相关论文
共 50 条
  • [41] Carboplatin, tegafur-uracil, leucovorin and concurrent radiotherapy for locally advanced head and neck squamous cell carcinoma. Results of the 2003-01 phase II GORTEC study
    Fesneau, M.
    Chapet, S.
    Martin, L.
    Pommier, P.
    Alfonsi, M.
    Laguerre, B.
    Feham, N.
    Berger, C.
    Calais, G.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 69 (03): : S423 - S423
  • [42] Phase 2 study of xevinapant plus chemoradiotherapy (CRT) vs placebo plus CRT in patients with unresected locally advanced squamous cell carcinoma of the head and neck (LA SCCHN): A post hoc activity analysis by blinded independent review committee evaluation
    Bourhis, Jean
    Eggleton, S. Peter
    Schroeder, Andreas
    Nauwelaerts, Heidi
    Bouisset, Florilene
    Sun, Xu-Shan
    Tao, Yungan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [43] Gefitinib plus concomitant boost accelerated radiation (AFX-CB) and concurrent weekly cisplatin for locally advanced unresectable squamous cell head and neck carcinomas (SCCHN): A phase II study
    Rueda, A.
    Medina, J. A.
    Mesia, R.
    Galiana, R.
    Vega, M. E.
    Collado, A.
    Cobo, M.
    Contreras, J.
    Margueli, M.
    Alba, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [44] Physician Perspectives on the Management of Patients with Resected High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck Who Are Ineligible to Receive Cisplatin: A Podcast
    Haddad, Robert I.
    Harrington, Kevin
    TARGETED ONCOLOGY, 2024, 19 (06) : 823 - 832
  • [45] ORCA-2: A phase I study of olaparib in addition to cisplatin-based concurrent chemoradiotherapy for patients with high risk locally advanced squamous cell carcinoma of the head and neck.
    Forster, Martin David
    Mendes, Ruheena
    Harrington, Kevin J.
    Urbano, Teresa Guerrero
    Baines, Helen
    Spanswick, Victoria J.
    Ensell, Leah
    Hartley, John A.
    Adeleke, Sola
    Gougis, Paul
    Leader, David
    McDowell, Cathy
    Lopes, Andre
    Teague, Jonathan
    Forsyth, Sharon
    Beare, Sandy
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [46] Preliminary results from a phase II, randomized, double-blind study of sorafenib plus doxorubicin versus placebo plus doxorubicin in patients with advanced hepatocellular carcinoma
    Abou Alfa, G. K.
    Johnson, P.
    Knox, J.
    Lacava, J.
    Leung, T.
    Mori, A.
    Leberre, M. A.
    Voliotis, D.
    Saltz, L.
    EJC SUPPLEMENTS, 2007, 5 (04): : 259 - 259
  • [47] Phase II randomized trial of surgery followed by chemoradiation plus cetuximab for high-risk squamous cell carcinoma of the head and neck (RTOG 0234)
    Harari, P. M.
    Harris, J.
    Kies, M. S.
    Myers, J. N.
    Machtay, M.
    Rotman, M. Z.
    Khuntia, D.
    Straube, W. L.
    Ang, K. K.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 69 (03): : S13 - S13
  • [48] A randomized phase II study evaluating concurrent or sequential fixed-dose immune therapy in combination with cisplatin and intensity-modulated radiotherapy in intermediate- or high-risk, previously untreated, locally advanced head and neck cancer (LA SCCHN).
    Clump, David Anthony
    Zandberg, Dan Paul
    Skinner, Heath Devin
    Ohr, James
    Fenton, Moon Jung
    Normolle, Daniel Paul
    Beitler, Jonathan Jay
    Bauman, Julie E.
    Ferris, Robert L.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [49] Concurrent chemoradiotherapy using carboplatin/cetuximab regimen in patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC) not eligible for high-dose cisplatin (HD-DDP)
    Saigal, Kunal
    Warsch, Sean
    Mandalia, Amar
    Samuels, Michael
    Tolba, Khaled A.
    Ikpeazu, Chukwuemeka
    Kwon, Deukwoo
    Santos, Edgardo S.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [50] Concomitant Adjuvant Chemoradiotherapy with Weekly Low-dose Cisplatin for High-risk Squamous Cell Carcinoma of the Head and Neck: a Phase II Prospective Trial
    Rampino, M.
    Ricardi, U.
    Munoz, F.
    Reali, A.
    Barone, C.
    Musu, A. R.
    Balcet, V.
    Franco, P.
    Grillo, R.
    Bustreo, S.
    Pecorari, G.
    Cavalot, A.
    Demo, R. Garzino
    Ciuffreda, L.
    Ragona, R.
    Schena, M.
    CLINICAL ONCOLOGY, 2011, 23 (02) : 134 - 140
12345